{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-061632","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2025-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.996079+00:00","generated_at":"2026-05-18T09:19:37.566051+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jasper reports 89% complete response in single-dose CSU cohorts, but drug lot issue delays Phase 2b to mid-2026","bullets":["8 of 9 (89%) patients in 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0).","8 of 11 (73%) in 180mg Q8W open-label extension achieved complete response at week 12.","Results from 240mg Q8W and 240mg→180mg Q8W cohorts confounded by drug product lot issue affecting 10 of 13 patients.","ETESIAN asthma study halted due to same lot issue; SCID development stopped; cost cutting and potential restructuring.","Additional BEACON data expected Q4 2025; Phase 2b CSU study start delayed to mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-061632","json":"https://secwatch.observer/filing/0001213900-25-061632.json","markdown":"https://secwatch.observer/filing/0001213900-25-061632.md","text":"https://secwatch.observer/filing/0001213900-25-061632.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025061632/0001213900-25-061632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025061632/ea0248252-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:19:37.566051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}